Why clinicians and investors are watching Mirum Pharmaceuticals after its EASL 2026 update
Find out how Mirum Pharmaceuticals’ EASL 2026 data could reshape rare liver disease treatment and investor sentiment.
Pharma & Biotech
Pharma & Biotech
Can volixibat and brelovitug expand Mirum Pharmaceuticals’ rare liver disease ambitions?
Mirum Pharmaceuticals’ EASL 2026 data deepen its rare liver disease strategy. Find out what changes for PSC, HDV and PFIC care.
Pharma & Biotech
Why Assembly Biosciences’ liver disease strategy now extends far beyond viral hepatitis
Assembly Biosciences is expanding ABI-6250 beyond HDV into PBC and PSC. Find out why NTCP inhibition is gaining industry attention.
Pharma & Biotech
Is volixibat the next major growth lever for Mirum Pharmaceuticals beyond LIVMARLI?
Mirum has commercial momentum. VISTAS will test whether volixibat can extend that rare liver disease story into PSC.